The Danish biotech and CRO company has announced its new 2030 strategy, in which it aims “to build a portfolio of 8-10 clinical stage assets across proprietary, partnered, and venture programs”.
Today, the Hørsholm based company has four such assets.
“Since our IPO in 2023, we have demonstrated our ability to translate scientific innovation into clinical-stage assets and establish valuable partnerships with leading pharmaceutical and biotech companies. Building on this strong foundation, our ambition toward 2030 is to significantly scale our innovation enigne, expand our clinical pipeline, and selectively broaden our reach into new therapeutic areas,” CEO Markus Rohrwild said in a press release.
BREAKING